For research use only. Not for therapeutic Use.
Sunitinib malate（Cat No.:I009650）is a multi-targeted tyrosine kinase inhibitor that blocks several receptor tyrosine kinases, including VEGFR, PDGFR, and c-Kit. It disrupts tumor angiogenesis and cell proliferation by inhibiting these pathways, making it highly effective in cancer treatment, particularly for renal cell carcinoma, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors. Sunitinib’s broad activity against multiple signaling pathways involved in tumor growth and metastasis has made it a crucial compound in oncology research, providing insights into targeted therapies for various malignancies.
| Catalog Number | I009650 |
| CAS Number | 341031-54-7 |
| Synonyms | SU11248; SU-11248; SU 11248; SU011248; Sunitinib malate; Sutent.;(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide malate |
| Molecular Formula | C22H27FN4O2 |
| Purity | 98% |
| Solubility | Soluble in DMSO, not in water |
| Appearance | Yellow solid powder |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| Related CAS | 557795-19-4 (free base) |
| IUPAC Name | N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide;(2S)-2-hydroxybutanedioic acid |
| InChI | InChI=1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1 |
| InChIKey | LBWFXVZLPYTWQI-IPOVEDGCSA-N |
| SMILES | CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C.C([C@@H](C(=O)O)O)C(=O)O |
| Reference | <br /> |
